Gemina Laboratories Ownership
| GLABF Stock | USD 0.80 0.04 4.76% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Gemina |
Gemina OTC Stock Ownership Analysis
About 56.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.08. Gemina Laboratories had not issued any dividends in recent years. Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. Gemina Laboratories operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5 people.The quote for Gemina Laboratories is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To learn more about Gemina Laboratories call the company at 604-760-1997 or check out https://www.geminalabs.com.Currently Active Assets on Macroaxis
Other Information on Investing in Gemina OTC Stock
Gemina Laboratories financial ratios help investors to determine whether Gemina OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Gemina with respect to the benefits of owning Gemina Laboratories security.